Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Li Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6872-2665; OpenAlex author ID A5102005867. Sources: ClinicalTrials.gov.

Their work

Papers
2 (first author 0, last author 1)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 trial · 2022: 1 trial · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. CLDN18.2-targeting STAR-T cell therapy for pancreatic cancer: a strategy to minimize gastric off-tumor toxicity compared to CLDN18.2 CAR-T. Last author DOI 10.1038/s41388-025-03414-z↗
  2. Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma. Co-author PMID 31815046↗

Trials 2

  1. Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T Principal investigator NCT05620732↗
  2. CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer Principal investigator NCT05143151↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guocheng Zhong · 1 shared paper, 2025 · strength 0.26
  2. Wei Zhang · 1 shared paper, 2025 · strength 0.26
  3. Vahid Yaghmai · 1 shared paper, 2019 · strength 0.09
  4. Jia Ying Yang · 1 shared paper, 2019 · strength 0.09
  5. Liang Pan · 1 shared paper, 2019 · strength 0.09
  6. Aydın Eresen · 1 shared paper, 2019 · strength 0.09
  7. Su Hu · 1 shared paper, 2019 · strength 0.09
  8. Zhuoli Zhang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.